29421-99-6

Basic information

• Product Name: 4-BROMO-5-METHYL-2-THIOPHENECARBOXYLIC ACID
• Synonyms: 4-BROMO-5-METHYL-2-THIOPHENECARBOXYLIC ACID;4-BROMO-5-METHYLTHIOPHENE-2-CARBOXYLIC ACID;AKOS B029947;ART-CHEM-BB B029947;VITAS-BB TBB010222;2-Thiophenecarboxylic acid, 4-bromo-5-methyl-
• CAS NO: 29421-99-6
• Molecular Formula: C₆H₅BrO₂S
• Molecular Weight: 221.07
• Mol File: 29421-99-6.mol
• Article Data: 10

Chemical Properties

• Melting Point: 198.5-199.5 °C
• Boiling Point: 324.3±42.0 °C(Predicted)
• Appearance: /
• Density: 1.784±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 3.70±0.10(Predicted)
• CAS DataBase Reference: 4-BROMO-5-METHYL-2-THIOPHENECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-5-METHYL-2-THIOPHENECARBOXYLIC ACID(29421-99-6)
• EPA Substance Registry System: 4-BROMO-5-METHYL-2-THIOPHENECARBOXYLIC ACID(29421-99-6)

Safety Data

• Hazardous Substances Data: 29421-99-6(Hazardous Substances Data)

Usage

General Description

4-Bromo-5-methyl-2-thiophenecarboxylic acid is a chemical compound with the molecular formula C7H5BrO2S. It is a derivative of thiophene and belongs to the class of carboxylic acids. 4-BROMO-5-METHYL-2-THIOPHENECARBOXYLIC ACID is used in organic synthesis and pharmaceutical research as a building block for the synthesis of various biologically active molecules. Its unique structure and properties make it a valuable intermediate in the production of drugs, agrochemicals, and other fine chemicals.

Upstream product

• 29421-73-6 3,5-dibromo-2-methylthiophene 
• 124-38-9 carbon dioxide 
• 1256286-44-8 ethyl 4-bromo-5-methylthiophene-2-carboxylate 
• 1918-79-2 2-methylthiophene-5-carboxylic acid 
• 554-14-3 2-Methylthiophene 

Downstream Products

• 237385-15-8 4-bromo-5-methylthiophene-2-carboxylic acid methyl ester 
• 478165-96-7 4-bromo-5-methylthiophene-2-carboxylic acid chloride 
• 288397-85-3 Isopropyl 5-methyl-4-(4-phenyl(1,3-thiazol-2-yl))thiophene-2-carboxylate 
• 237385-20-5 methyl 4-[4-(3,4-dimethoxyphenyl)(1,3-thiazol-2-yl)]-5-methylthiophene-2-carboxylate 
• 1109284-49-2 methyl 5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-carboxylate 
• 1047644-65-4 N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-4-(1,4-dimethyl-1H-pyrazol-5-yl)-5-methyl-2-thiophenecarboxamide hydrochloride 
• 1047628-82-9 N-((1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-5-methyl-4-(1-methyl-4-propyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide 
• 1047646-05-8 N-[(1S)-2-amino-1-(cyclohexylmethyl)ethyl]-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-5-methyl-2-thiophenecarboxamide hydrochloride 
• 1047628-64-7 N-((1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-5-methyl-4-[1-methyl-4-(1-methylethyl)-1H-pyrazol-5-yl]-2-thiophenecarboxamide 
• 1047645-96-4 4-(1,4-dimethyl-1H-pyrazol-5-yl)-N-((1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-5-methyl-2-thiophenecarboxamide 
• 1047628-39-6 4-(4-bromo-1-methyl-1H-pyrazol-5-yl)-N-{(1S)-2-cyclohexyl-1-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]ethyl}-5-methyl-2-thiophenecarboxamide 
• 1047646-04-7 4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-N-{(1S)-2-cyclohexyl-1-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]ethyl}-5-methyl-2-thiophenecarboxamide 
• 1047646-06-9 N-{(1S)-2-cyclohexyl-1-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]ethyl}-5-methyl-4-(1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide 
• 1047627-39-3 N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-5-methyl-4-(1-methyl-4-propyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide 

Relevant articles and documents

2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS

2-(1H-lndole-3-carbonyl)-thiazole-4-carboxamide derivatives and the corresponding imidazole, oxazole and thiophene derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 27 to 32 and 59 to 219; examples 1 to 8; compounds 1-1 to 1-97; tables 1-a, 2 and 3).

IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.

Direct bromination of ethyl 5-alkylthiophene-2-carboxylates

Approaches to brominated thiophene-2-carboxylic acids by electrophilic bromination of the corresponding acids and esters were compared and investigated. A synthetic route was developed involving direct bromination of ethyl 5-alkylthiophene-2-carboxylates followed by saponification of the resulting ethyl 5-alkyl-4-bromothiophene-2-carboxylates. The key bromination step is selective in dichloromethane solution at 0-5 °C and furnishes the corresponding ethyl 5-alkyl-4-bromothiophene-2-carboxylates in excellent yields. No migration or isomerization of the alkyl substituents was observed. Georg Thieme Verlag Stuttgart New York.